BioWorld

March 1, 2010

IPO Activity Poised to Pop with Anthera, Aveo and Trius on Deck

It's been nearly a month since Ironwood Pharmaceuticals Inc. tested the biotech initial public offering waters, and now three more biotechs are queued up to price IPOs over the next three weeks. (BioWorld Today) Read More

HCV Combo Approach Keeping Partner Hopes Bright for Idenix

'Clear and Testable Hypothesis' on Pediatric Asthma's Roots

Amicus Adds $18.5M Publicly for Phase III Amigal Program

Collins: NIH Funding Boosts Economy, Spurs Job Growth

Move Over, Cerezyme; Shire's Vpriv Gets Official FDA Nod

Other News To Note

Vital Signs for March 1, 2010

Clinic Roundup

Bench Press

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...